Mass Tort brief
Teva Navigates Critical US Legal Trials Over Paragard and Generic Pricing
Israel's flagship drugmaker faces pivotal late-2026 court dates in Georgia and Connecticut as peer settlements narrow litigation targets.
Mass Tort
Peer settlements leave Teva exposed as the sole main target in upcoming state price-fixing trials — raising potential antitrust liabilities for the Israeli drugmaker.
BackgroundState law enforcement officers can join forces in multi-state antitrust litigation to recover damages for overcharged consumers and public healthcare programs. Teva Pharmaceuticals USA remains the main defendant after competitors opted to settle out of court.
- The Glenmark agreement pushes total state settlement recoveries to $66.95M, isolating Teva as the remaining primary target in the lead action.
- State prosecutors allege generic drug executives held secret meetings and colluded on market allocation, driving up costs for hospitals and pharmacies.
- A trial defeat in Connecticut could expose Teva to treble damages and severe financial penalties across dozens of state jurisdictions.
Mass Tort
Teva faces a decisive second bellwether trial over Paragard breakage claims — setting the financial baseline for thousands of pending US injury lawsuits.
BackgroundTeva Pharmaceutical Industries is Israel's largest drugmaker, dual-listed on the Tel Aviv Stock Exchange and New York Stock Exchange. Multi-district litigation consolidates similar injury claims before one judge to test evidence and establish valuation ranges before trial.
- Teva won a complete defense verdict in the first bellwether trial in February 2026, establishing a strong initial defense baseline against liability claims.
- Plaintiffs allege Teva failed to warn physicians and patients about device breakage risks, leading to surgical interventions and permanent physical injuries.
- The September trial outcome will dictate global settlement leverage for over 3,800 lawsuits, directly impacting Teva's legal reserves and balance sheet.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
